Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $25 and keeps an Outperform rating on the shares. The firm attended Definium’s Investor and Analyst Day, and was impressed by the depth of insights from management and key opinion leaders on the Phase 3 program and commercial opportunity for DT120, reinforcing Oppenheimer’s conviction.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Definium Therapeutics: Strengthened Investment Case and Multi-Indication Upside Ahead of Key Phase 3 Readouts
- Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety
- Definium Therapeutics highlights advancement of DT120 ODT
- Definium Therapeutics: Policy Tailwinds and Late-Stage Clinical Momentum Support Attractive Risk‑Reward and Higher $38 Price Target
- Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!